[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fCfJFoTeQqp4YMgOaGFY4vGDZZEJnTWyApB4B1PDpVpY":3},{"answer":4,"createTime":5,"id":6,"options":7,"origin":12,"question":16,"related":17,"source":27,"type":28},[],"2026-05-13 16:29:09",359149984,[8,9,10,11],"物理包埋法","高温烧结法","化学键合法","静电作用法",{"courseId":13,"courseImg":14,"courseName":15},"53e1d2ef4961cca8eea3e23969ad2cb9","https:\u002F\u002Ftihai-oss-cloud.itihey.com\u002Fimg\u002F03a579384a6dc297c89809b582fcc767.png","默认课程","下列不属于纳米药物载体制备方法的是( )",[18,29,38,41,50,59,68,77,87,96],{"answer":19,"createTime":5,"id":20,"options":21,"question":26,"source":27,"type":28},[],359149982,[22,23,24,25],"会使药物分子失去生物活性","粒径过大","制备复杂","具有主动靶向性","一代普通脂质体的主要缺点是( )","v1",0,{"answer":30,"createTime":5,"id":31,"options":32,"question":37,"source":27,"type":28},[],359149983,[33,34,35,36],"晶粒易长大或团聚","超导相向正常相的转变","纳米材料密度增大","金属纳米相材料电阻增大与临界尺寸现象","下列关于纳米材料小尺寸效应主要影响的描述,错误的是( )",{"answer":39,"createTime":5,"id":6,"options":40,"question":16,"source":27,"type":28},[],[8,9,10,11],{"answer":42,"createTime":5,"id":43,"options":44,"question":49,"source":27,"type":28},[],359149985,[45,46,47,48],"多层同心的多层脂质体(MLV)","大单层脂质体(LUV)","非同心多囊泡脂质体(MVL)","小单层脂质体(SUV)","脂质体按不同直径大小以及内囊数目可分为多种类型,直径小于 100nm 的是( )",{"answer":51,"createTime":5,"id":52,"options":53,"question":58,"source":27,"type":28},[],359149986,[54,55,56,57],"力","声","化学稳定性","光","小尺寸效应中,当超细微粒的尺寸与光波波长等物理尺寸相当或更小时,晶体周期性的边界条件被破坏,不会导致( )特性呈现新的效应",{"answer":60,"createTime":5,"id":61,"options":62,"question":67,"source":27,"type":28},[],359149987,[63,64,65,66],"聚磷腈","聚碳酸酯","壳聚糖","聚酯类","下列属于天然高分子载体材料的是( )",{"answer":69,"createTime":5,"id":70,"options":71,"question":76,"source":27,"type":28},[],359149988,[72,73,74,75],"半衰期和组织分布","溶解度","颜色和气味","酸碱度","构建纳米药物载体的主要目标之一是调控药物在体内的( )",{"answer":78,"createTime":79,"id":80,"options":81,"question":86,"source":27,"type":28},[],"2026-05-06 12:22:34",359149989,[82,83,84,85],"血液循环","肿瘤渗透","肿瘤抑制","细胞摄取","纳米药物载体向实体瘤传输过程的关键级联步骤不包括( )",{"answer":88,"createTime":5,"id":89,"options":90,"question":95,"source":27,"type":28},[],359149990,[91,92,93,94],"粒径 130 nm 的紫杉醇 - 白蛋白结合型纳米颗粒","粒径 130 nm 的雷帕霉素 - 白蛋白结合型纳米颗粒","粒径 130 nm 的 17AAG - 白蛋白结合型纳米颗粒","粒径 130 nm 的多西紫杉醇 - 白蛋白结合型纳米颗粒","以 "凯素" 为代表的白蛋白结合技术制备的纳米药物是( )",{"answer":97,"createTime":5,"id":98,"options":99,"question":104,"source":27,"type":28},[],359149991,[100,101,102,103],"聚乙二醇 - 聚酯","聚乳酸羟基乙酸","阳离子聚合物","聚左旋赖氨酸","纳米药物载体中聚合物胶束比较常见,其中应用最为广泛的是( )"]